Abstract | Small, noncoding microRNAs (miRNAs) regulate diverse biological functions in the liver and increasing evidence suggests that they have a role in liver pathology. This Review summarizes advances in the field of miRNAs in liver diseases, inflammation and cirrhosis. MicroRNA-122, the most abundant miRNA in hepatocytes, has well-defined roles in HCV replication, and data indicate that it also serves as a viable therapeutic target. The role of miR-122 is also emerging in other liver diseases. Ample evidence exists for the important regulatory potential of other miRNAs in conditions associated with liver inflammation related to alcohol use, the metabolic syndrome or autoimmune processes. In addition, a broad array of miRNAs have been associated with the development of liver fibrosis both in animal models and human studies. The significance of the function and cellular distribution of miRNAs in the liver and the potential of miRNAs as a means of communication between cells and organs is discussed as well as the emerging utility of circulating miRNAs as biomarkers of different forms of liver damage and as early markers of disease and progression in hepatocellular carcinoma. Importantly, miRNA modulation in the liver represents a new therapeutic approach in the treatment armamentarium of hepatologists in the future.
Introduction
MicroRNAs (miRNAs), discovered by Ambros and c olleagues in 1993, 1 are small noncoding RNAs, 18-24 nucleotides in length, that regulate gene expression by binding to mRNAs to interfere with the process of translation. 2 Genes that encode miRNAs are transcribed from DNA to a primary transcript (pri-miRNAs), which is processed into a short precursor (pre-miRNA) and then exported into the cytoplasm where it is further processed into a mature, single stranded miRNA 2, 3 ( Figure 1 ). The biogenesis of miRNAs can be regulated at the tr anscriptional level by specific transcription factors and at the post-transcriptional level by changes in processing. Evidence suggests that single nucleotide polymorphisms in miRNA genes might also modulate miRNA activity and function. 4 In most cases, miRNAs repress their targets via interaction with the 3' untranslated region (UTR), and this change is detectable at the RNA level; 2, 3 however, miRNAs that interact with their targets in a non-3' UTR-dependent or non-seed-dependent fashion cause upregulation of their targets. There are ~1,400 mammalian miRNAs 5 and each miRNA can influence hundreds of gene transcripts. More than one miRNA can regulate each specific mRNA, which creates substantial complexity in their capacity to modulate fundamental biological processes.
MiRNAs target and regulate essentially all b iological processes and cell types, including those in the liver, and influence complex programmes of gene expression in virtually all cellular processes. Numerous reports have demonstrated that alterations in intracellular miRNAs correlate with various liver diseases including viral hepatitis, alcoholic and nonalcoholic steatohepatitis, drug-induced liver injury, autoimmune liver disease and ischaemia-reperfusion injury. Evidence is also emerging that miRNA expression profiles are distinct between liver diseases with different aetiologies.
This Review summarizes current knowledge on the role of different miRNAs in liver diseases and highlights the functions of the most relevant miRNAs that have specific roles in liver damage, hepatocyte functions, viral hepatitis, alcoholic and nonalcoholic liver disease, liver fibrosis and hepatocellular carcinoma (HCC). In addition, we discuss the emerging utility of miRNAs as potential biomarkers in liver diseases and promising aspects of miRNAs in t herapeutic interventions for liver diseases.
Role of microRNAs in the liver
MiRNAs regulate lipid and glucose metabolism Excess accumulation of hepatic triglycerides and fatty acids is characteristic of several liver diseases including alcoholic liver disease (ALD), NAFLD and NASH. Several lines of evidence suggest that miRNAs have a crucial role in m etabolic homeostasis (reviewed extensively elsewhere 6 ). In the liver, miR-122 affects various genes involved in hepatic cholesterol and lipid metabolism, thereby having a central role in maintaining liver homeostasis. Inhibition of miR-122 using antisense approaches resulted in reduction of plasma cholesterol levels in mice 7 and chimpanzees. 8, 9 A reduction in hepatic miR-122 expression has been reported in both human NASH and animal models of this disease, 10, 11 as well as in ALD in mice. 12 Intriguingly, two studies have demonstrated that deletion of the gene encoding miR-122 in mice leads to the development of steatohepatitis, fibrosis and HCC. 13, 14 Despite the fact that miR-122-deficient mice (liver-specific knockouts and germ line knockouts) had lower levels of serum cholesterol, LDL and serum triglyceride than wild-type mice, they developed steatohepatitis and HCC. 13, 14 Reduced levels of HDL were also observed in these knockout mice. 13, 14 miR-33, miR-34, miR-103, miR-104 and miR-370 also modulate lipid and cholesterol regulatory genes. 6 miR-370 affects lipid metabolism by targeting the mitochondrial enzyme, carnitine palmitoyl transferase, which is involved in the transport of long-chain fatty acids across the membrane. 15 miR-34a targets hepatic SIRT1, and an increase in levels of miR-34a with a concurrent decrease in Sirt1 levels was found in fatty livers of diet-induced obese mice 16 (reviewed elsewhere 17 ). Meng et al. 18 demonstrated an induction in miR-34a in ALD both in humans and mice; miR-34a regulates SIRT1 and caspase-2 levels and contributes to hepatic steatosis in this disease (Figure 2 ). miR-27b has also been described as a regulatory hub in lipid metabolism, potentially affecting both the liver and the heart. 19 These findings indicate that dysregulation of miRNAs contributes to metabolic abnormalities; hence miRNA-based therapeutics might deliver promising results in this setting.
MicroRNAs regulate inflammation
Various factors contribute to liver inflammation, including viral and bacterial infections, metabolic disorders, toxins and dietary factors. Growing evidence indicates that miRNAs have a fine-tuning role in liver inflammation by targeting various signalling molecules. A plethora of miRNAs has been implicated in inflam matory responses: miR-155, miR-132, miR-125b, miR-146a, miR-150, miR-181, let-7 and miR-21.
20,21 miR-155 is involved both in innate and adaptive immune responses. 22 miRNA-155 has received attention for its role in various liver diseases. Induction in miR-155 expression has been reported in mouse models of NASH and alcoholic steatohepatits. 10, 23 miR-155 levels were increased in Kupffer cells after alcohol feeding, and TNF has been identified as a target of miR-155 to promote liver inflammation 23 ( Figure 2) . In mice receiving a choline-deficient and amino acid-defined (CDAA) diet, miR-155 was associated with HCC, in which it regulates C/EBP β levels. 10 In addition, we have reported the increased expression of miR-155 in peripheral monocytes from patients with chronic HCV whereas no increase was found in patients who responded to treatment. 24 Similarly, two other reports have described the induction of the BIC gene (a precursor of mature miR-155) 25 and mature miRNA-155 in peripheral blood mononuclear cells (PBMCs) of patients infected with HCV. 26 Interestingly, these reports also found that patients who eliminated HCV RNA successfully after antiviral treatment showed no induction of miR-155. 25, 26 Remarkably, the hepatic levels of miR-155 were also increased in patients with HCV and were shown to promote HCC through Wnt signalling. 27 The role of miRNAs in HCV-induced hepatitis is shown in Figure 3 .
Unlike miR-155, miR-146a is a negative regulator of TLR signalling; it dampens proinflammatory responses via TRAF6 and IRAK-1. Consistent with its negative regulatory role in inflammation, mice deficient in miR-146a
Key points ■ MicroRNAs (miRNAs) are encoded by genes and exert their intracellular effects by targeting post-transcriptional events on target genes ■ MiRNAs fine-tune all physiological and many pathological processes that are fundamental to normal liver functions and liver disease ■ The distribution and function of some miRNAs is cell-specific, and hepatocytes have the highest abundance of microRNA-122 expression in the body ■ In the liver, miRNAs have been shown to regulate processes such as inflammation, fibrosis, and lipid and glucose metabolism ■ Dysregulation in miRNAs is associated with liver diseases, such as hepatocellular carcinoma, viral hepatitis, alcoholic and nonalcoholic steatohepatitis and drug-induced liver injury ■ Extracellular miRNAs could serve as biomarkers of liver disease, but specificity might be a limitation acquire hyperinflammation and myloproliferative p henotypes owing to hyperactivation of NF-κB. 28 miR-132 is known to have a pivotal role in peripheral inflammation. 29 Although its role in the brain has been widely studied, limited information is available on the role of miR-132 in immune regulation. Induction of miR-132 has been reported in the liver and Kupffer cells after chronic alcohol administration in mice. In the cytoplasm, DICER, along with TRBP, cleaves pre-miRNA to form mature miRNA (miRNA duplex). The strand is selected depending upon the stability, and the functional strand is loaded together with Ago2 and GW182 into the RISC. The less stable strand of miRNA gets degraded. Depending on the complementarity of the seed region of mature miRNA to the 3' UTR of the target mRNA gene, target mRNA either undergoes cleavage, translational repression or activation. Abbreviations: RISC, RNA-induced silencing complex; pre-miRNA, precursor miRNA; pri-miRNA, primary miRNA.
by inhibiting expression of the p300 transcriptional coactivator during Kaposi sarcoma-associated herpesvirus infection. 30 Intriguingly, miR-132 was shown to promote inflam mation in a dipocytes during nutrient starvation via a SIRT1-p65 axis, 31 suggesting a cell-specific or stimulispecific role. Further studies are warranted to define its role in liver inflammation and immunity.
An unexpected role of miR-122 is emerging in liver inflammation. miR-122-deficient mice showed upregulation of Ccl2, which resulted in the intrahepatic recruitment of CD11b hi Gr1 + inflammatory cells. These cells were the source of proinflammatory cytokines, IL-6 and TNF.
14 Interestingly, serum miR-122 has been proposed as a marker of necroinflammation in patients with chronic HCV infection. 32 Our own study also supports this notion as we found a correlation between serum miR-122 and serum miR-155 levels to be a marker of inflammation in patients with chronic HCV infection. 24 These observations suggest that alterations in expression of specific miRNAs in liver inflammation might herald general inflammation or be disease-specific.
MicroRNAs in apoptosis and necrosis
In a mouse model of acute liver failure induced by D-galactosamine/lipopolysaccharide (LPS), miR-15b and miR-16 regulated TNF-mediated apoptosis via Bcl2, an anti-apoptotic gene. 33 Inhibition of miR-15b and miR-16 resulted in reduced hepatic apoptosis and TNF production, which indicates a pro-apoptotic role for these miRNAs. miR-1187 is implicated in hepatocyte apoptosis via its targeting of caspase-8 in D-galactosamine/LPS-induced acute liver failure; 34 the hepatic expression of miR-1187 was decreased with a concomitant increase in caspase-8 expression. 34 In FASLG (CD95) receptor-induced apoptosis, the global loss of miRNAs in hepatic cells was associated with increased cell death, under scoring the importance of miRNAs in hepatocytes. 35 miR-221 was highly induced in response to apoptosis, and delivery of miR-221 in vivo by adeno-associated virus serotype 8 (AAV8) resulted in delayed FAS-induced fulminant liver failure in mice. 35 miR-221 regulates hepatic expression of BBC3 (a pro-apoptotic gene; also known as PUMA) and protects hepatocytes from apoptosis, suggesting a p leiotropic role of miRNAs in acute liver failure.
MicroRNAs affect cell cycle and proliferation
Various miRNAs control hepatocyte proliferation, and miR-21 has been shown to regulate various genes involved in the cell cycle and DNA synthesis. After performing partial hepatectomy in mice, miR-21 is induced and it inhibits hepatocyte DNA synthesis via its effect on Btg2 and FoxM1 (secondary target).
36 miR-21 also has a role in hepato cyte proliferation by promoting cyclin D1 translation. 37 Inhibition of induced miR-21 after two-thirds partial hepatectomy impaired the progression of hepatocytes into S phase via RhoB, which is involved in cyclin D1 trans lation. 37 Contrary to miR-21, miR-26a is downregulated after partial hepatectomy and promotes hepatocyte proliferation by regulating G1/S-specific c yclin-D2 (CCND2) and G1/S-specific cyclin-E2 (CCNE2) cell cycle protein expression. 38 miR-217 has an antiproliferative role and methylation of its promoter region results in its decrease during liver regeneration. 39 Decreases in levels of miR-127 inversely correlated with levels of B-cell lymphoma 6 protein homolog (Bcl6) and N-lysine methyltransferase SETD8 24 h after partial h epatectomy. 39 miR-221 is identified as a pro-proliferativ e miRNA as it regulates hepatocyte proliferation during liver r egeneration by affecting the expression of Arnt. 40 MicroRNAs and epithelial-mesenchymal transition Epithelial-mesenchymal transition (EMT) contributes to liver regeneration and is potentially involved in cancers in the liver. EMT involves the termination of epithelial tight junctions, modulation of adherens junctions, remodelling of the cytoskeleton and loss of cell polarity. 41 Little is known about the role of miRNAs in EMT regulation in liver diseases. However, given that different cells undergo EMT in various liver diseases, it is likely that miRNAs have a crucial and unidentified role in this process. miR-155 is highly induced in TGF-β-induced EMT in NMuMG epithelial cells, in which it has a role in cell migration and invasion by targeting RhoA kinase. 42 Various studies have demonstrated the critical role of members of the miRNA-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) in EMT by modulating the expression of ZEB1 and ZEB2, the transcriptional repressors of cadherin-1 (E-cadherin). [43] [44] [45] Consistent with these findings, miR-200a and miR-200b are upregulated in liver fibrosis. 46 A common network of miRNAs (miR-106a, miR-106b, miR-18a, miR-18b, miR-17, miR-93, miR-301a and miR-130b) that regulate embryonic stem cell self-renewal are also involved in EMT of hepatocytes via the PTEN-TGF-β axis, implicating their potential to transform normal hepatocytes into neoplastic cells. 47 These studies have opened a new avenue of research to explore the dual role of miRNAs in EMT and embryonic stem cell processes.
MicroRNAs and liver fibrosis
The importance of miRNAs in liver fibrosis has been reviewed extensively elsewhere, 48 thus here we focus on emerging miRNAs identified in liver fibrosis. miRNAs are involved in regulation of liver fibrosis at multiple levels. Key cytokines and growth factors determining liver fibrosis regulate expression of profibrogenic and anti fibrogenic miRNAs (summarized elsewhere 49 ). Hepatic stellate cells (HSCs), the primary cell type that contributes to liver fibrosis, undergo proliferation and differentiatio n into myofibroblast-like cells upon fibrogenic injury of the liver. A broad variety of miRNAs have been identified in regulating HSC activation (Figure 4 ). Increased serum levels of miR-571 have been proposed as a potential biomarker of liver fibrosis, and serum levels of miR-542, miR-652 and miR-181b are decreased in cirrhosis 50, 51 ( Figure 4 ). miR-19b and miR-29 have been identified as antifibrotic genes on the basis of their effects on HSCs. [52] [53] [54] Interestingly, miR-29 has also been identified as a regulator of disease-associated pathways in biliary atresia in a mouse model, which suggests that individual miRNAs have re gulatory potential in different cell types in the liver. 55 TGF-β, a modulator of fibrosis, induces miR-21 in patients infected with HCV, in whom it downregulates SMAD7, a negative regulator of TGF-β signalling. This finding suggests positive feedback regulation of miR-21 and TGF-β. 56 miR-199a, miR-199a*, miR-200a and miR-200b levels are highly associated with progression of liver fibrosis both in patients with chronic HCV i nfection and in mice with CCl 4 -induced fibrosis. 46 A decrease in miRNA-150 and miRNA-194 was found in HSCs of bile-duct-ligated rats; these miRNAs targeted c-Myc and Rac-1, respectively, and thereby inhibited HSC activation. 57 miR-199 and miR-200 families have been shown to promote liver fibrosis by enhancing fibrotic genes (such as those that encode α1 pro collagen, c ollagenase 3 and metalloproteinase inhibitor 1). 46 miR-146a, which regulates SMAD4, was downregulated in HSCs in CCl 4 -induced liver fibrosis. 58 Overexpression of miR-146a repressed TGF-β-induced HSC proliferation and increased HSC apoptosis. 58 miR-122 is required for normal liver homoeostasis and decreased levels of this miRNA have deleterious effects on the liver. In fact, miR-122-deficient mice develop st eatohepatitis and fibrosis. 13 KLF6, a profibrogenic factor, was identified as a target of miR-122 and a role for the miR-122a-KLF6 axis has been proposed in liver fibrosis. 13 We have shown that chronic alcohol use can modulate miR-122 expression, and decreased expression of this miRNA was found in the livers of mice fed with alcohol. 12 Given that prolonged chronic alcohol use can lead to liver fibrosis, a decrease in miR-122 after alcohol consumption suggests a direct or indirect role for miR-122 in alcohol-induced fibrosis. Consistent with this notion, a study revealed the role of miR-122 in HSCs; expression of miR-122 was decreased in activated HSCs in a CCl 4 -induced liver fibrosis mouse model. 59 miRNA-122 negatively regulates liver fibrosis by targeting the gene that encodes transmembrane prolyl 4-hydroxylas e, which is involved in the process of collagen maturation. 59 However, the underlying mechanisms of decreased miR-122 in ALD and its precise role in different cell types is yet to be defined. To conclude, it seems that the majority of miRNAs modulate HSCs and therefore hold promise for therapeutic interventions in liver fibrosis.
Emerging role of organelle-associated microRNAs Advances in miRNA detection have revealed the unexpected existence of certain miRNAs in various organelles such as mitochondria and the nucleus 60, 61 (summarized in Table 1 ). The first study demonstrating the existence of mitochondrial miRNA (mito-miRNA) was carried out in rat livers, and it was postulated that these mito-miRNA s might be involved in processes such as apop tosis, cell proliferation and differentiation. 61 Streptozotocin treatment induces type 1 diabetes in mice and results in the alteration of mito-miRNAs. 62 In particular, levels of miR-494, miR-202-5p, miR-134 and miR-155 are increased, whereas levels of miR-122 are decreased in the liver mitochondria of these mice. 62 Interestingly, Argonaute-2 (Ago2, the effector of the miRNA-induced silencing complex that mediates mRNA repression) was also detected in mitochondrial lysates, raising the possibility that mitochondrial-associate d miRNAs might be functional. The finding of the presence of Ago2 and miRNA in mitochondria could be extrapolated to have a role in liver diseases as mitochondria have a major role in liver disease pathogenesis; a functional RISC (RNA-induced silencing complex) along with miRNAs might have a direct role in modulating mitochondrial proteins. In this context, Das and colleagues showed for the first time that miR-181c can translocate to mitochondria where it targets the mitochondria genome via Cox1 resulting in electron transport chain complex IV r emodelling and mitochondrial dysfunction. 60 Emerging studies suggest that miRNAs might have biological functions that are distinct from canonical 3' UTR target mRNA repression. miR-29b, miR-320 and miR-671 are mostly abundant in the nucleus and regulate gene transcription. [63] [64] [65] However, the distribution and function of mitochondrial and nuclear miRNAs in liver diseases is yet to be explored.
Contribution of microRNAs to liver diseases

Viral hepatitis
The discovery of the involvement of miR-122 in the HCV replication process is one of the best examples of the potential importance of miRNAs and targeted miRNA-based therapeutic approaches. 66 Inhibition of miR-122 using antisense approaches such as antagomirs and 'locked nucleic acids' (LNAs) has reduced HCV replication in mice 7 and chimpanzees. 9 Early phase IIa human clinical trials indicate that inhibition of miR-122 can inhibit HCV levels in patients with chronic HCV infection.
67 miRNAs are usually thought to control the expression of the target gene. However, miR-122 paradoxically increases the replication of HCV by interacting with the 5'-UTR of HCV RNA. 68 This unique requirement of miR-122 for HCV repli cation is not fully understood. The possibility that miR-122 might be involved in HCV RNA degrad ation, in its localization to functional replication complexes, or in the translation to replication switch have been suggested and are yet to be explored. 69 A study showed that Ago2 protein is directly and efficiently recruited to the HCV 5'-UTR by miR-122 but not by an unrelated miRNA; this finding suggests that direct base-pairing is used to guide miR-122 and Ago2 to the HCV RNA, resultin g in RNA stability and translation stimulation. 70 miRNA-122 can also be the target of disease modifying factors in HCV infection via inhibition of cyclin G1, which has been identified as a host factor in HCV replication. In this context, alcohol consumption is known to enhance HCV replication, and a role for miR-122 in this process has been demonstrated; 71 alcohol treatment in HCV-infected hepatoma cells increases levels of miR-122, which in turn modulates cyclin G1 expression. 71 In addition, miR-122 upregulation by alcohol was associated with increased levels of the P body protein, GW182 and heat shock protein 90, which contributed to enhance HCV replication. 72 An additional consideration is that regulation of HCV replication by miR-122 has been investigated in isolated hepatocytes or hepatoma cells whereas changes in total liver levels of miR-122 expressio n might reflect miR-122 regulation in other cell types.
The miRNA expression profile in patients with chronic HCV, HBV and HCC was found to be different although a cluster of 19 miRNAs were commonly affected in both HCV and HBV. 73 In HBV-infected livers, pathways related to cell death, DNA damage, recombination and signal transduction were activated. On the other hand, in HCV infected livers, pathways related to immune responses, antigen presentation, cell cycle and lipid metabolism were abnormally expressed. 73 miR-122-induced downregu lation of heme-oxygenase-1 was shown to negatively affect miR-122-mediated suppression of HBV, indicating that host and viral factors might both involve miRNA regulation. 74 miRNA-449a has been demonstrated to have a role in modulating expression of CHI3L1 (which encodes chitinase-3-like protein 1, an inflammatory marker [also known as YKL40]), through targeting the components of the NOTCH signalling pathway after HCV infection, meaning that this miRNA might act as a bridge between inflammation and fibrosis 75 ( Figure 3 ). 
Drug-induced liver injury
Most available data on miRNAs in drug-induced liver injury (DILI) are related to acetaminophen-induced acute liver failure. Levels of miR-122 and miR-192 are decreased whereas levels of miR-710 and miR-711 are increased in the livers of mice administered with acetaminophen. 76 The mechanisms causing a decrease in levels of miR-122 and miR-192 after DILI are not clear, but the most probable explanation is that hepatocyte damage releases these miRNAs into the circulation. Tetrachlorodibenzo-p-dioxin (TCDD)-induced liver damage in mice results in a time-dependent decrease in levels of miR-101a and miR-122 in the liver.
77 Cox2 (also known as Ptgs2), a miR-101a target gene, was increased in mice exposed to TCDD. 77 In general, various miRNAs regulate P450 enzymes and nuclear receptors that are involved in drug metabolism. 78 miR-378 has been shown to regulate Cyp2e1, an enzyme that is involved in the metabolism of acetaminophen, alcohol and CCl 4 , 79 again indicating that miRNAs might have an important role in drug metabolism and toxicity. Thus, improved understanding of the role of miRNAs in drug toxicity might facilitate drug development.
Alcoholic steatohepatitis and NASH
Aside from the abnormalities in miR-122 expression described earlier, increased expression of miR-320, miR-486, miR-705 and miR-1224, and decreased expression of several other miRNAs (miR-27b, miR-214, miR-199a, miR-192 and miR-183) was found in mouse livers after chronic alcohol feeding. 80 We have also found increased expression of miR-132 in mice fed with alcohol; this miRNA has been identified as a critical regulator of inflammation along with miR-155. 21, 29, 81 In addition, miR-212 is involved in alcohol-induced gut permeability. 82 Alcohol consumption resulted in increased miR-212 expression in the gut, which in turn inhibited ZO-1 protein levels (a tight junction protein). 82 miR-217 is involved in alcohol-induced steatosis by regulating SIRT1, which affects essential metabolic regulatory transcription factors. 83 Alcohol also modulates the expression of miR-199 in rat liver sinusoidal endothelial cells and human endothelial cells. 84 A decrease in miR-199 was associated with an increase in endothelin-1 (ET-1) and hypoxia-inducible factor-1α (HIF-1α), which have a crucial role in inflammation and steatosis. These studies suggest that alcohol modulates miRNAs in different cell types of the liver to amplify its effect. Whether similar miRNAs are involved in NASH remains to be determined. Kupffer cell activation is common both in alcoholic steatohepatitis and NASH, thus it is tempting to speculate that the miRNA-155 upregulation that occurs in Kupffer cells in ALD 23 might also be present in NASH. Altered hepatic miRNA expression has been found in patients with NASH.
10 miR-122 levels in the liver are substantially decreased in patients with NASH and it has been proposed that these decreased levels in the liver contribute to altered hepatic lipid metabolism. 10 These findings have been corroborated in a study in miR-122-deficient mice, in which liver steatosis was found. 13, 14 These findings are presumably related to reduced levels of miR-122 in hepatocytes; however, a role for miR-122 in inflam matory and other cells is yet to be evaluated. Cell-specific targeting of miR-122 is now possible using recombinant adeno-associated virus (rAAV)-mediated and 'Tough Decoy' (TuD)-directed inhibition of this miRNA in h epatocytes in vivo in animal models. 85 Hepatocellular carcinoma HCC is the third leading cause of cancer-related mortality worldwide. 86 Key processes in cancer biology, including cell cycle and proliferation, are regulated by miRNAs at multiple levels; therefore, it is not unexpected that alterations in miRNAs contribute to the development of HCC. Human miRNA genome (miRNome) analyses of samples of healthy liver, liver with hepatitis and hepatocellular carcin oma revealed the downregulation of miR-199a/b-3p in HCC, which was correlated with poor survival. 87 miR-199a/b-3p is involved in regulation of the PAK4/ Raf/MEK/ERK pathway, which suppresses HCC growth. Furthermore, the delivery of miR-199a/b-3p mimics via AAV8 to HCC-bearing mice inhibited tumour growth, indicating that this miRNA is a potential target for HCC treatment. 87 Intriguingly, the majority of miRNAs that localize to genomic fragile sites are associated with cancer. 88 In line with this notion, miR-151 is frequently localized to the amplified region of chromosome 8q24.3 and associated with intrahepatic metastasis of HCC. 89 miR-151 has a vital role in metastasis by activating RAC1, CDC42 and other Rho GTPase genes by targeting RhoGDIA (a metastasis suppressor) and also enhances cell motility and spreading by acting synergistically along with FAK. 89 Various studies have suggested the involvement of miR-221 in HCC. miR-221 is upregulated in HCC 
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and controls various genes involved in the cell cycle (such as CDKN1C and CDKN1B 90 ) and DNA damage (DDIT4). 91 In a mouse model, inhibition of miR-221 with Chol-anti-miR-221 (a cholesterol-modified isoform of anti-miR-221) resulted in reduction of tumour cell proliferation and increased levels of markers of apop tosis and cell-cycle arrest and, as a consequence, increased survival. 92 From these studies it is apparent that antimiR-221 could be exploited as a potential therapeutic target in HCC-related malignancies.
By contrast, miR-29 is downregulated in HCC and targets various anti-apoptotic genes, such as BCL2, MCL1 and MMP2. 93, 94 It is becoming increasingly evident that miRNAs not only regulate genes involved in tumour angiogenesis, invasion and metastasis but also modulate the expression of other noncoding RNA, hence amplifying their effect. In this regard, miR-29 has been shown to regulate the long noncoding RNA MEG3 by modulating its methylation through effects on DNMT1 and DNMT3b. 95 In addition, certain miRNA expression profiles are characteristic of HCC.
46,96 Downregulation of miR-24a, miR-26a, miR-15a/b, miR-150 and miR-195 was found in a myc-induced mouse model of HCC. 97 Cyclin D2 and E2 are regulated by miR-26a and this miRNA can also induce G1 arrest in human liver cancer cells. 97 In human HCC, miR-26a was decreased and AAV-vector-driven overexpression of miR-26a might prevent liver tumours. 97 Interestingly, a gender difference in miRNA expression has been observed. 98 The expression of miR-26a and miR-26b in nontumour liver tissue was higher in women than in men, whereas HCC tissue regardless of sex had reduced miR-26 expression compared with noncancerous tissues. 98 Transcriptome analysis revealed that activation of signalling pathways between NF-κB and IL-6 might be involved in tumour development. 98 Other abnormally expressed miRNAs in HCC include an increase in levels of miR-21, miR-22 and miR-517a 46, 96, 99, 100 and a decrease in levels of miR-122, miR-20 family, miR-124 and let-7 family members. 100 Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain in metastatic properties, which indicates an i mportant role for miR-122 in hepatocarcinogenesis. 101 Other liver diseases Altered hepatic miRNA expression has been found in patients with primary biliary cirrhosis (PBC). 102 Interestingly, miR-122a was downregulated along with miR-16a, whereas miR-328 and miR-299-5p were increased. 102 These miRNAs are associated with processes such as cell proliferation, apoptosis, inflammation, oxidativ e stress and metabolism. Upregulation of miR-506 was associated with decreased CI -/HCO3 -anion exchange 2 (AE2) expression in the biliary epithelium of patients with PBC. 103 AE2 is involved in intra cellular pH homeostasis and secretin-stimulated biliary bicarbonat e secretion, and common genetic variations in AE2/SLC4A2 are associated with disease susceptibility in patients with PBC. 103, 104 The important role of AE2 has also been demonstrated in AE2-deficient mice, which showed immunologic and hepatobiliary changes resembling human PBC. 105 Similarly, PBMCs from patients with PBC showed dysregulation of various miRNAs that are involved in cell differentiation, cell cycle and MAPK, TGF-β and Wnt signalling pathways. 106 Studies suggest that liver-specific miRNA-122 controls systemic iron homeostasis, which contributes to hemochromatosis. 107 The role of miRNAs in autoimmune hepatitis deserves further investigation.
Circulating miRNAs as biomarkers of disease
Studies have documented the presence of miRNAs in the circulation, extracellular spaces and in various body fluids, including bile. [108] [109] [110] Circulating miRNAs are distributed in various forms, including in association with Ago2, 111 vesicles such as exosomes, 112 macrovesicles or apoptotic bodies 113 or bind HDL 114 ( Figure 5 ). The cellular release processes of miRNAs and/or factors that might govern these associations are yet to be understood. In addition to miRNAs, the components of RISC proteins such as Ago2 and its interacting partner GW182 have been found in exosomes and microvesicles. 115 Moreover, miRNAs are associated with lipid-based carriers and lipidfree proteins and the transfer of miRNAs between cells has a potential role in intracellular communication. 116 The biodistribution of extracellular miRNAs and their potential functional role on target cells remain to be elicited. It is tempting to speculate that miRNAs in the circulation serve as 'messengers' and have the potential to influence functions of cells or tissues distant from their site of origin. In support of this idea, emerging reports indicate that miRNAs in plasma are delivered to recipient cells for uptake. 114 Indeed, miRNAs might provide a means of 'communication' between tissues, organs or even species (Table 2) . Consistent with this notion, a study found that miRNA-168a, which is specifically expressed in rice, was absorbed in the gut of both humans and mice, entered the circulation and had a b iological effect on decreasing LDL receptor function. 117 Because of their great stability in the serum and plasma, miRNAs are considered to be attractive biomarkers for liver disease ( Figure 5 ). Numerous studies have reported increased levels of circulating miR-122 in liver diseases with different aetiologies, which suggests that miR-122 in the serum seems to be a potential marker of liver injury in general rather than indicating a specific aetiology of liver disease; increased levels of miR-122 have been found in HCV infection, 24 (Table 3) . As miR-122 is abundant in hepatocytes, it is tempting to speculate that miR-122 is released to the circulation after hepatocyte injury through yet to be defined mechanisms.
Apart from miR-122, other miRNA signatures have also been revealed in liver diseases. We have shown the induction of the inflammation-related miRNA, miR-155, in ALD and in TLR9+TLR4-induced liver inflammation in the liver and circulation. 12 Chronic HCV i nfection causes liver inflammation and consistent with this fact, induction of miR-155 was found both in serum and peripheral monocytes of patients with chronic HCV infection. 24, 27 Another liver miRNA, miR-196 was increased in the serum and plasma of patients with HBV infection, 119 NAFLD 125 and drug overdose (acetaminophen). 124 miRNA-34a, which regulates lipid and cholesterol metabolism, was found to be upregulated in patients with NAFLD and HCV. 118 Liver fibrosis and/or cirrhosi s was associated with increased levels of miR-513-3p and miR-571 and a reduction in levels of miR-652 and miR-29. 50 A number of miRNAs, such as miR-21, miR-199a, miR-1885-5p and miR-16, were increased in the circulation of patients with HCC. 32, 122, 123 In biliary atresia, circulating levels of the miR-200b/429 cluster are elevated in infants and have promising diagnostic clinical potential. 127 Interestingly, exosomal miRNA expression pattern is unique to liver diseases and varies between grade and stages of liver disease, which emphasizes their potential as diagnostics biomarkers. 128 Moreover, circulating miR-122 could be used as a general marker of liver injury and might have better sensitivity than alanine aminotransferase. 12, 76, 118, 124 MicroRNAs as therapeutic targets
The potential therapeutic application of targeting miRNAs is receiving increasing attention in liver diseases and has been reviewed elsewhere. 129 Both inhib ition and overexpression of miRNAs are therapeutically in reach with current technologies. Perhaps the most advanced therapeutic discovery at this time is related to inhibition of miRNA-122 in chronic HCV infection. On the basis of successful preclinical studies with an anti-miR-122 LNA inhibitor, clinical trials are on going. Results of the initial clinical trial with miravirsen, an antisense oligo nucleotide targeting miR-122, report prolonged dose-dependent reduction in HCV RNA levels without evidence of viral resistance. 130 The long half-life of LNAs and the minimal adverse effect profile promises future development of this approach in human disease. 129, 131 Delivery systems for small noncoding RNAs can also be approached with AAV delivery of mRNA inhibitors or precursors.
Advances in human AAV modifications have the potential for cell-specific delivery of a target miRNA precursor or antagonist. Delivery of small duplex RNAs can be achieved using cationic lipid-based and nano particle [131] [132] [133] [134] Lipid-based and gold nanoparticles are both under investigation for small RNAbased therapy. miRNA manipulation might be an optimal approach for conditions in which the expression level of a specific miRNA target needs adjustment rather than complete inhibition or upregulation. Given the 'fine-tuning' effects of miRNAs on target gene expression and function, incremental modulation of target genes of miRNAs is a realistic therapeutic approach. For example, in liver diseases that involve moderate inflammation in their pathogenesis, such as alcoholic or nonalcoholic liver diseases, targeting inflammatory mediators via miRNA might be sufficient to restore homeostasis instead of fully inhibiting vital signalling pathways. Further investi gations will explore possibilities for miRNA targeting in therapeutic intervention for liver diseases.
Conclusions
The biological significance and utility of miRNAs in liver disease is a rapidly growing field. It is increasingly evident that in addition to the 'traditional' role of miRNAs in inhibition of target gene expression, miRNAs have more complex and diverse functions that can be specific for individual miRNAs, the cell type or the tissue environment. Although some features of miRNA biology-such as their effects on target genes-are well described, the cell-specific regulatory potential and disease-specific alterations of miRNAs in the liver await further investigation. Another emerging area is the biological significance of extracellular miRNAs. These miRNAs might be particularly important in liver diseases in which some miRNAs enter the systemic circulation in increased quantities during liver damage. Both the quantity and 'quality' defined by packaging of miRNAs could also be of importance for circulating miRNAs with respect to their biodistribution, b ioavailability and/or target effects.
At this time, little is known about whether the association of miRNAs with Ago2, exosomes, lipid particles or other forms has any bearing on their half-life, biological distribution, cellular uptake and/or target cell or organ effects. It is generally established that circulating miRNAs are stable compared with many other biological markers and that this property has contributed to the rapid explosion of biomarker discovery in circulating miRNAs. Important advances are evolving in HCC-specific miRNA biomarkers; identification of circulating miRNA profiles that are specific for a particular liver disease rather than liver injury in general is more challenging. Finally, understanding of the role and alterations of miRNAs in cellular functions and disease processes in the liver provides a strong basis for targeting miRNAs in treatment development. We believe that it is realistic to expect that miRNA-based therapies will be part of the therapeutic armamentarium for hepatologists in the next decade.
Review criteria
A PubMed search was carried out using "microRNA" as a key word in combination with "liver disease", "HCC", "HCV", "inflammation", "alcohol", "NASH", "fibrosis", "circulating miRNA", "diagnostics", "biomarkers" and "therapeutic molecules". The relevant review articles were also searched for cross-references.
